| p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa LJ Valente, DHD Gray, EM Michalak, J Pinon-Hofbauer, A Egle, CL Scott, ... Cell reports 3 (5), 1339-1345, 2013 | 312 | 2013 |
| Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53 GL Kelly, S Grabow, SP Glaser, L Fitzsimmons, BJ Aubrey, T Okamoto, ... Genes & development 28 (1), 58-70, 2014 | 183 | 2014 |
| A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer SS Mello, LJ Valente, N Raj, JA Seoane, BM Flowers, J McClendon, ... Cancer Cell 32 (4), 460-473. e6, 2017 | 162 | 2017 |
| DNA repair processes are critical mediators of p53-dependent tumor suppression A Janic, LJ Valente, MJ Wakefield, L Di Stefano, L Milla, S Wilcox, H Yang, ... Nature medicine 24 (7), 947-953, 2018 | 131 | 2018 |
| The role of the apoptotic machinery in tumor suppression ARD Delbridge, LJ Valente, A Strasser Cold Spring Harbor perspectives in biology 4 (11), a008789, 2012 | 131 | 2012 |
| MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice S Grabow, ARD Delbridge, LJ Valente, A Strasser Blood, The Journal of the American Society of Hematology 124 (26), 3939-3946, 2014 | 46 | 2014 |
| Role of p63 and the Notch pathway in cochlea development and sensorineural deafness A Terrinoni, V Serra, E Bruno, A Strasser, E Valente, ER Flores, ... Proceedings of the National Academy of Sciences 110 (18), 7300-7305, 2013 | 45 | 2013 |
| Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells LJ Valente, BJ Aubrey, MJ Herold, GL Kelly, L Happo, CL Scott, ... Cell reports 14 (8), 1858-1866, 2016 | 38 | 2016 |
| Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53 LJ Valente, S Grabow, CJ Vandenberg, A Strasser, A Janic Oncogene, 2015 | 34 | 2015 |
| p53 deficiency triggers dysregulation of diverse cellular processes in physiological oxygen LJ Valente, A Tarangelo, AM Li, M Naciri, N Raj, AM Boutelle, Y Li, ... Journal of Cell Biology 219 (11), 2020 | 27 | 2020 |
| Distinct target genes and effector processes appear to be critical for p53-activated responses to acute DNA damage versus p53-mediated tumour suppression LJ Valente, A Strasser BioDiscovery 8, e8948, 2013 | 16 | 2013 |
| Polymerase delta-interacting protein 38 (PDIP38) modulates the stability and activity of the mitochondrial AAA+ protease CLPXP PR Strack, EJ Brodie, H Zhan, VJ Schuenemann, LJ Valente, T Saiyed, ... Communications biology 3 (1), 1-12, 2020 | 10 | 2020 |
| GigaAssay – An adaptable high-throughput saturation mutagenesis assay platform MRS Ronald Benjamin, Christopher J. Giacoletto, Zachary T. Fitz Hugh ... Genomics 114 (4), 2022 | 7 | 2022 |
| P53 orchestrates a complex symphony of cellular processes during oncosuppression LJ Valente, LD Attardi Molecular & Cellular Oncology 8 (1), 1852066, 2021 | 5 | 2021 |
| p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013; 3: 1339–45 LJ Valente, DH Gray, EM Michalak, J Pinon-Hofbauer, A Egle, CL Scott, ... External Resources Pubmed/Medline (NLM) Crossref (DOI), 2011 | 5 | 2011 |
| Data supporting a saturation mutagenesis assay for Tat-driven transcription with the GigaAssay R Benjamin, CJ Giacoletto, ZT FitzHugh, D Eames, L Buczek, X Wu, ... Data in Brief 45, 108641, 2022 | 2 | 2022 |
| PDIP38 is a novel adaptor-like modulator of the mitochondrial AAA+ protease CLPXP PR Strack, EJ Brodie, H Zhan, VJ Schuenemann, LJ Valente, T Saiyed, ... bioRxiv, 2020 | 1 | 2020 |
| Targeting of MCL-1 kills MYC-driven mouse and human lymphomas GL Kelly, S Grabow, SP Glaser | | |
